f-6

NSC-632839 (Ubiquitin Isopeptidase Inhibitor II) is a nonselective isopeptidase inhibitor, which inhibits USP2 (EC50: 45±4 μM), USP7 (EC50: 37±1 μM), and SENP2 (EC50: 9.8±1.8 μM).

PF-610355 is a long-acting and potent β2-adrenergic receptor agonist (EC50: 0.26 nM).PF-610355 can be used to study asthma and COPD.

PF-6689840 is a potent and selective Type II PTK6/Brk inhibitor with IC50 of 54 nM in biochemical assays; inhibits PTK6 phosphorylation at Y342 in engineered HET293T cells overexpressing PTK6 WT with IC50 of 0.25 uM; demonstrates superior kinase selectivity compared to the Type I inhibitors; inhibits tumor cell growth, which is independent of PTK6 expression levels in cells.

PF-610355 HCl is a selective and potent β2-adrenergic receptor agonist, a bronchodilator, and is used in the study of asthma and chronic obstructive pulmonary disease.

STF-62247 is TGN inhibitor with IC50 of 0.625 μM and 16 μM in RCC4 and RCC4/VHL cells, respectively.

Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 is a drug-linker conjugate for ADCs. It consists of a topoisomerase 1 inhibitor (Topi MF-6) and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala). This compound is utilized in the synthesis of antibody-drug conjugates (ADCs).

GNF-6231 is a potent, selective, and orally bioavailable Porcupine inhibitor that blocks Wnt signaling.

UPF-648 sodium salt is an inhibitor of kynurenine 3-monooxygenase (KMO) and exhibits highly active at 1 uM (81 ± 10% KMO inhibition).

UPF-648 is a potent kynurenine 3-monooxygenase (KMO) inhibitor, demonstrating high activity at 1 µM with 81 ± 10% inhibition.

CHF-6333 CATION is a compound that inhibits human neutrophil elastase.

CHF-6333 is an inhibitor targeting human neutrophil elastase.

AF-615 is an innovative inhibitor of the CDT1/Geminin protein complex, capable of inducing DNA damage and cell death in cancer cells.

MORF-627 is an orally active selective inhibitor of integrin αvβ6 (integrinαvβ6), with an IC50 of 9.2 nM as measured in a human serum ligand binding assay. It effectively inhibits αvβ6-mediated activation of TGF-β1 with an IC50 of 2.63 nM and suppresses SMAD2/3 phosphorylation, showing an IC50 of 8.3 nM. Additionally, MORF-627 ameliorates bleomycin-induced pulmonary fibrosis in mice.

CHF-6550 is an antagonist of the muscarinic M3 receptor (M3 receptor) and an agonist of the β2 adrenoceptor (β2 adrenoceptor), with pKi values of 9.3 and 10.6, respectively. It exhibits favorable hepatocyte clearance in rat models and demonstrates good pharmacokinetic properties in guinea pigs.

Topi MF-6 is a DNA topoisomerase I (Top1) inhibitor with excellent cytotoxic properties against gastrointestinal cancer cells. It can be utilized as an ADC payload.

PF-6274484, a high affinity, irreversible covalent inhibitor of EGFR kinase with Ki of 0.14 nM, inhibits the autophosphorylation of wild-type EGFR in A549 cells and EGFRL858R/T790M in H1975 cells with IC50 of 5.8 nM and 6.6 nM, respectively.

PF-6422899 irreversibly inhibits EGFR kinase activity by binding covalently to active-site cysteine residues in the ATP binding pocket of EGFR.

PF-670462 is a potent (IC50 = 7.7 ± 2.2 nM) and selective (>30-fold with respect to 42 additional kinases) inhibitor of CK1ε in isolated enzyme preparations.

PF-6808472 is a cell-permeable covalent kinase probe that reacts with conserved lysine residues within the ATP-binding site of kinases, thereby binding to and labelling multiple kinases such as CDK1/2/4.

(3S,4R)-PF-6683324 is a pro-myosin-related kinase (Trk) inhibitor with research potential for pain and cancer.

MCUF-651 is a guanylyl cyclase A receptor positive allosteric modulators, EC50=0.45 μM.

CHF-6366 is a dual-action chemical compound acting as a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist, with respective pK i values of 10.4 and 11.4. Additionally, it exhibits weak calcium channel inhibitory properties (IC 50 ~50 μM) and demonstrates the ability to inhibit bronchoconstriction in guinea pigs, making it a viable candidate for chronic obstructive pulmonary disease (COPD) research.

GNF-6 (Compound 14), an ATP competitive inhibitor, inhibits the gatekeeper threonine residue mutation of BCR-ABL-T315I with IC50 values of 0.25 μM for c-ABL-T334I, 0.09 μM for BCR-ABL, and 0.590 μM for BCR-ABL-T315I variants. It disrupts the assembly of the hydrophobic spine (a network of hydrophobic interactions), locking the kinase in an inactive 'DFG-out' conformation [1].

CHF-6523 is a PI3K δ inhibitor that can be used in research related to chronic obstructive pulmonary disease (COPD).